

Global Radioimmunotherapy Market, Dosage, Price & Clinical Pipeline Outlook 2022

<https://marketpublishers.com/r/G54967A4F73EN.html>

Date: March 2018

Pages: 200

Price: US\$ 2,400.00 (Single User License)

ID: G54967A4F73EN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

“Global Radioimmunotherapy Market, Dosage, Price & Clinical Pipeline Outlook 2022”

Report Highlights:

Need & Efficacy of Radioimmunotherapy

Components of Radioimmunotherapy

Clinical Status of Radioimmunotherapy in Various Cancer Therapy

Emerging Opportunities in the Radioimmunotherapy Segment

Patent, Dosage & Price Analysis

Antibodies in Radioimmunotherapy

Global Radioimmunotherapy Clinical Pipeline: 68 Drugs

Clinical Pipeline analysis by Phase

Cancer therapy is one of the most intensive areas of research globally. The severity and prevalence associated with cancer makes it one of the most feared ailments worldwide. Research conducted by various international organizations like the world health organization and the Centre for disease control clearly indicates the rising prevalence of

cancer globally which is bound to be a major burden to the global healthcare sector in the coming decades. This has led to an increased demand of cancer therapeutics with high efficacy and less toxicity.

Out of all the existing cancer therapeutics being researched upon, immunotherapy is being anticipated as the most promising and viable segment of modern cancer therapeutics. Cancer Immunotherapy is the use of the body's own immune system to treat cancer. Years of research has proved that the immune system can be trained to identify and eliminate particular cells from the body by giving suitable cues. This unique property of the immune system has widely been utilized to treat diseases by modulating immune responses.

It was however observed that the efficacy of cancer therapy significantly improved when combined with traditional radiation therapy which then gave rise to a new class of cancer therapy known as the cancer Radioimmunotherapy. The amalgamation of radiation therapy with immunotherapy proved to be a breakthrough method of cancer therapy with impressive results in cancers such as the Non- Hodgkin lymphoma; which was earlier considered to be a non-treatable cancer.

Ibritumomab tiuxetan and Iodine (131I) tositumomab are the two most popular Radio immunotherapeutics that received FDA Approval in the year 2002 and 2003 respectively. As of now only these two radio immunotherapeutics have been marketed globally for the treatment of Non Hodgkin lymphoma under the brand name Zevalin(Ibrumomab tiuxetan) and Bexxar(Tositumomab).

The excellent results obtained in cancer Radioimmunotherapy in the past & current research has led to the segment progressing rapidly in terms of both clinical and commercial aspects with increased attention from pharmaceutical and healthcare sectors around the world. While it has already been approved as a standard treatment for Non Hodgkin Lymphoma and follicular lymphoma, it has yet to prove its clinical efficacy in other cancer types.

An insight into the clinical pipeline and current status of all the cancer types associated with Radioimmunotherapy presents an optimistic picture regarding its improvement with efficacy. With the advancement in science and technology, the Radioimmunotherapy segment is bound to progress at a rapid rate thus making it a promising cancer therapeutic of the future.

Kuick Research report on global Radioimmunotherapy aims at providing an in-depth

analysis of the market with special emphasis on the Global market size, current market trend and factors affecting the future market growth. Additionally the report includes comparative price, dosage and therapy cost analysis of marketed Radioimmunotherapy drugs providing a detailed insight into the Radioimmunotherapy marketed products.

Contents

1. CANCER RADIOIMMUNOTHERAPY - AMALGAMATION THERAPY FOR ELEVATED EFFICACY

- 1.1 Prologue to Cancer Radioimmunotherapy
- 1.2 History & Evolution of Cancer Radioimmunotherapy

2. RADIOIMMUNOTHERAPY - AN INSIGHT INTO ITS NEED & EFFICACY

- 2.1 High Unmet Medical Needs & Failure of Conventional Cancer Therapeutics
- 2.2 Targeted Therapy for Higher Efficacy
- 2.3 Superiority of Radioimmunotherapy over Other Cancer Therapeutics

3. FEATURES OF RADIOIMMUNOTHERAPY

- 3.1 Approved Benefits Associated with Radioimmunotherapy
- 3.2 Radioimmunotherapy using Monoclonal Antibodies

4. COMPONENTS OF RADIOIMMUNOTHERAPY

- 4.1 Tumor Antigens - Potential Targets for Monoclonal Antibodies
- 4.2 Radionuclides
- 4.3 Antibodies - Key Components in Radioimmunotherapy

5. RADIOIMMUNOTHERAPY - PRINCIPLE & ACTION

6. CLINICAL STATUS OF RADIOIMMUNOTHERAPY IN VARIOUS CANCER THERAPY

- 6.1 Non Hodgkin Lymphoma (NHL)
- 6.2 Follicular Lymphoma
- 6.3 Solid Tumors
- 6.4 Breast Cancer
- 6.5 Ovarian Cancer
- 6.6 Osteosarcoma
- 6.7 Neuroblastoma
- 6.8 Prostate Cancer

7. EMERGING OPPORTUNITIES & AVENUES IN THE RADIOIMMUNOTHERAPY SEGMENT

- 7.1 Immune Checkpoint Inhibitors & Radioactive Iodine in Cancer Radioimmunotherapy
- 7.2 Nanotechnologically Created Radiotracer: For Efficient Delivery of Radioactivity in Tumor Cells

8. RADIOIMMUNOTHERAPY MARKET - DOSAGE & PRICE ANALYSIS OF MONOCLONAL ANTIBODIES INVOLVED

- 8.1 Ibritumomab tiuxetan (Zevalin) & Rituxan– Dosage & Price Analysis in Follicular B-cell Non-Hodgkin Lymphoma
- 8.2 Zevalin & Rituxan: Therapy Cost Analysis
- 8.3 Comparative Cost Analysis of Radioimmunotherapy with Traditional Cancer therapy Methods
- 8.4 Tositumomab and iodine I 131 Tositumomab (Bexxar)

9. MARKET PERFORMANCE & TRENDS IN RADIOIMMUNOTHERAPEUTICS SEGMENT

- 9.1 Better Safety & Efficacy but Limited Growth Opportunity
- 9.2 Decreasing Sales of Zevalin Threatening the Radioimmunotherapy Market
- 9.3 Involvement of Blockbuster Therapeutics in Radioimmunotherapy to Ensure Stability in the Future
- 9.4 Emerging Pattern of Radioimmunotherapy Drug Referrals

10. RADIOIMMUNOTHERAPY MONOCLONAL ANTIBODIES CURRENTLY UNDER DEVELOPMENT & THEIR MARKET POTENTIAL

- 10.1 Epratuzumab
- 10.2 Lintuzumab
- 10.3 Labetuzumab
- 10.4 Trastuzumab (Herceptin)

11. ANTIBODIES IN RADIOIMMUNOTHERAPY - PATENT ANALYSIS

12. REGIONAL ANALYSIS OF THE RADIOIMMUNOTHERAPY MARKET

- 12.1 North America

- 12.1.1 United States (US)
- 12.1.2 Canada
- 12.2 Europe
 - 12.2.1 Germany
 - 12.2.2 France
 - 12.2.3 United Kingdom (UK)
 - 12.2.4 Rest of Europe
- 12.3 Asia - Pacific
 - 12.3.1 China & India
 - 12.3.2 Japan
 - 12.3.3 Australia
- 12.4 Rest of the World

13. GLOBAL RADIOIMMUNOTHERAPY MARKET DRIVING PARAMETERS

14. RADIOIMMUNOTHERAPY - OVERCOMING THE CHALLENGES & SHORTCOMINGS

15. FUTURE FORECAST & PERSPECTIVE REGARDING THE IMMUNOTHERAPY SEGMENT

- 15.1 Global Approval of Radioimmunotherapy to Enhance Market Growth in Future
- 15.2 Radiopharmaceutical Market & its Impact on the Radioimmunotherapy market growth
- 15.3 Other Market Propelling Factors

16. GLOBAL RADIOIMMUNOTHERAPY CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE

- 16.1 Global Radiopharmaceuticals Pipeline Overview
- 16.2 Unknown
- 16.3 Research
- 16.4 Preclinical
- 16.5 Clinical
- 16.6 Phase-0
- 16.7 Phase-I
- 16.8 Phase-I/II
- 16.9 Phase-II
- 16.10 Phase-III

16.11 Preregistration

16.12 Registered

17. COMPETITIVE LANDSCAPE

17.1 Bayer Healthcare Pharmaceuticals

17.2 BioSynthema

17.3 Clarity Pharmaceuticals

17.4 Curasight

17.5 Endocyte

17.6 Immunomedics

17.7 Molecular Insight Pharmaceuticals

17.8 Nordic Nanovector

17.9 PDL Biopharma

17.10 Philogen

17.11 RadioMedix

17.12 Stella Pharma

17.13 Telix Pharmaceuticals

List Of Figures

LIST OF FIGURES

Figure 1-1: Evolution of Radiopharmaceuticals & Radioimmunotherapy

Figure 2-1: Need for Radioimmunotherapy

Figure 4-1: Components of Radioimmunotherapy

Figure 4-2: Monoclonal Antibodies - Vital Target Sites in Immunotherapy

Figure 4-3: Antigen Target & Their Therapy Antibodies in Radioimmunotherapy

Figure 4-4: Development of a Radionuclide

Figure 4-5: Half Life of Various Radioimmunotherapy Nuclides

Figure 4-6: Tissue Penetration of Key Radionuclides Used in Immunotherapy (mm)

Figure 4-7: Monoclonal Antibody in Radioimmunotherapy

Figure 5-1: Fundamental Working Mechanism of Radioimmunotherapy

Figure 6-1: Global - Non Hodgkin Lymphoma Incidence & Mortality by Numbers, 2018

Figure 6-2: Clinical Efficacy- Rituximab v/s Zevalin Standalone Therapy (%)

Figure 6-3: Global - Ovarian Cancer Incidence (per 100,000 Females), 2018

Figure 7-1: Humanized Antibodies - High Efficacy due to decreased Immunogenicity

Figure 8-1: Zevalin - Overview of Dosage Schedule

Figure 8-2: Zevalin- Dosage (milliCurie/kg)

Figure 8-3: Zevalin - Cost Analysis (US\$/ml), 2018

Figure 8-4: Rituxan - Dosage (mg/m²)

Figure 8-5: Rituxan - Cost Analysis (US\$/ml), 2018

Figure 8-6: Dosage - Median Radiation Dosimetry(Y-90 Zevalin cGy /mCi)

Figure 8-7: Zevalin & Rituxan: Average Therapy Cost Analysis (US\$), 2018

Figure 8-8: Comparative Cost Analysis: Radioimmunotherapy v/s Traditional Cancer Therapeutics

Figure 8-9: Overview - Ositumab Dosing Schedule in Non-Hodgkin Lymphoma

Figure 8-10: Tositumab & I 131 Tositumab- Dosage (mg/Session)

Figure 8-11: Radiation dosimetry in Bexaar Therapy

Figure 9-1: Global - Zevalin Sales by Year (US\$ Million), 2013-2016

Figure 9-2: Global - Rituxan Market Size (%), 2018

Figure 9-3: Global- Rituxan Sales (US\$ Billion), 2015 & 2016

Figure 9-4: Global – Tositumomab Referral Trend Analysis by Practice (%), 2018

Figure 11-1: Patent Status - Monoclonal Antibody in Radioimmunotherapy, 2018

Figure 12-1: Canada - Comparative Price Analysis, RIT v/s Non-RIT treatment Modality (US\$), 2018

Figure 13-1: Driving Factors of the Radioimmunotherapy Segment

Figure 14-1: Challenging Aspects of the Radioimmunotherapy Market

Figure 15-1: Zevalin - Sales Future Forecast (US\$ Million), 2016-2022

Figure 15-2: Rituxan - Future Sales Forecast (US\$ Billion), 2016-2022

Figure 15-3: Probability of Radioimmunotherapy Market Growth (%), 2018

Figure 15-4: Global - Radioimmunotherapy Market Size by End User (%), 2018

Figure 16-1: Global - Radiopharmaceuticals Clinical Pipeline by Phase (%), 2018 till 2022

Figure 16-2: Global - Radiopharmaceuticals Clinical Pipeline by Phase (Number), 2018 till 2022

I would like to order

Product name: Global Radioimmunotherapy Market, Dosage, Price & Clinical Pipeline Outlook 2022

Product link: <https://marketpublishers.com/r/G54967A4F73EN.html>

Price: US\$ 2,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G54967A4F73EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970